HIV protease resistance and viral fitness
- PMID: 19372875
- DOI: 10.1097/COH.0b013e32801682f6
HIV protease resistance and viral fitness
Abstract
Purpose of review: This review focuses on the evolution of protease inhibitor resistance and replication capacity in the presence and absence of protease inhibitor pressure.
Recent findings: Classically, HIV escapes through mutations in the protease itself causing a decrease in affinity to the inhibitor, leading to resistance. These changes also affect the binding of the enzyme to the natural substrate, and as a consequence cause a decrease in replication capacity of the virus. Continuous replication of these viruses may result in the acquisition of compensatory changes, which will fixate the drug-resistant variant in the viral population. Furthermore, novel treatment strategies have been developed to combat the development of classic protease inhibitor resistance. Using these strategies, the development of resistance in the viral protease is blocked because single or double mutations do not confer significant resistance. Alternative protease inhibitor resistance pathways are described, which enable the virus to escape these novel strategies.
Summary: Suboptimal protease inhibitor pressure clearly results in the selection of mutations conferring resistance and in the acquisition of mutations compensating the initial reduction in viral replicative capacity. The major implications of the selection of these compensatory changes on evolution in the absence of protease inhibitor pressure are discussed.
Similar articles
-
Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations.Curr Opin HIV AIDS. 2007 Mar;2(2):81-7. doi: 10.1097/COH.0b013e328051b4e8. Curr Opin HIV AIDS. 2007. PMID: 19372871
-
Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.Handb Exp Pharmacol. 2009;(189):299-320. doi: 10.1007/978-3-540-79086-0_11. Handb Exp Pharmacol. 2009. PMID: 19048205 Review.
-
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.J Med Virol. 2008 Dec;80(12):2053-63. doi: 10.1002/jmv.21329. J Med Virol. 2008. PMID: 19040279
-
Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.J Infect Dis. 2009 Sep 1;200(5):698-709. doi: 10.1086/605329. J Infect Dis. 2009. PMID: 19627247
-
HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.AIDS Rev. 2009 Jul-Sep;11(3):165-73. AIDS Rev. 2009. PMID: 19654858 Review.
Cited by
-
Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.J Virol. 2013 Aug;87(15):8524-34. doi: 10.1128/JVI.01240-13. Epub 2013 May 29. J Virol. 2013. PMID: 23720716 Free PMC article.
-
Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.J Virol. 2010 Jul;84(13):6799-809. doi: 10.1128/JVI.00294-10. Epub 2010 Apr 21. J Virol. 2010. PMID: 20410281 Free PMC article.
-
HIV Protease: Historical Perspective and Current Research.Viruses. 2021 May 6;13(5):839. doi: 10.3390/v13050839. Viruses. 2021. PMID: 34066370 Free PMC article. Review.
-
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.Antimicrob Agents Chemother. 2017 Feb 23;61(3):e00498-16. doi: 10.1128/AAC.00498-16. Print 2017 Mar. Antimicrob Agents Chemother. 2017. PMID: 27956422 Free PMC article.
-
Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence.Sci Rep. 2018 Oct 24;8(1):15739. doi: 10.1038/s41598-018-34058-7. Sci Rep. 2018. PMID: 30356083 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials